A new study shows TAK-981, a potent and selective inhibitor of SUMOylation, induces IFN1 signaling and protects the IFN1 pathway from inactivation within tumors. The inhibitor activates T cells and dendritic cells that present antigens to the adaptive immune system, in both mouse models and in cell lines. The activity of the potential cancer drug depends on the IFN1 pathway and adaptive immunity to suppress tumor growth. Combined with anti-PD1 antibody TAK-981 demonstrates prolonged survival in tumor-bearing mice and increased activation of natural killer cells and CD8 expressing T cells.
A new convection-enhanced macroencapsulation device (ceMED) designed by bioengineers from Brigham and Women’s Hospital, Harvard University, and the University of Massachusetts Medical School offers the potential of faster and more effective treatment for people with type 1 diabetes. Whereas traditional MEDs rely on diffusion, the new MED uses convection to create a continuous flow of nutrients through the capsule improving the number of cells that can be accommodated in each cartridge and increasing their survival, glucose sensitivity and insulin secretion.
Goblet cells that line the major airways in the lungs and produce protective mucus in healthy lungs, are abnormally increased in number in lung diseases resulting in excessive mucus secretion. A new study from scientists at Boston University identify regulatory signals that determine the fate of progenitor cells that produce these goblet cells. Targeting these regulatory signals may provide therapeutic directions for restricting the production of goblet cells in a number of lung diseases such as asthma, COPD (Chronic obstructive pulmonary disease), cystic fibrosis, and chronic bronchitis.